A squamous cell carcinoma (SCC) of the skin is generally considered large when it reaches 2 centimeters (about ¾ of an inch) in diameter. That’s the threshold used by the major staging systems to separate lower-risk tumors from those with significantly higher chances of spreading. Tumors that reach 4 centimeters or more enter an even higher risk category, and those exceeding 5 centimeters are sometimes described in medical literature as “giant,” though there’s no formal definition for that term.
The 2-Centimeter Threshold
In the most widely used staging system (AJCC 8th edition), a tumor smaller than 2 cm is classified as T1, the lowest stage. Once it hits 2 cm, it moves to T2. At 4 cm or larger, it jumps to T3. This matters because the size directly correlates with how likely the cancer is to spread. Tumors under 2 cm have a metastasis rate of about 9%, while those over 2 cm metastasize at rates up to 30%.
The Brigham and Women’s Hospital staging system, which many dermatologists consider more precise, treats tumor diameter of 2 cm or greater as one of four key high-risk features. The others are poor differentiation (how abnormal the cells look under a microscope), nerve invasion, and growth beyond the fat layer beneath the skin. A tumor with two or three of these features falls into the T2b category, which despite representing only about 5% of all skin SCCs, accounts for roughly 60% of poor outcomes like spread to lymph nodes or death from the disease.
Size Isn’t the Only Measure
Diameter tells part of the story, but depth matters just as much. The critical depth threshold is 6 millimeters. A tumor that has grown more than 6 mm deep into the skin automatically qualifies as T3 in the AJCC system, regardless of how wide it is on the surface. Every major staging system and set of clinical guidelines agrees on this 6 mm cutoff as the line between lower-risk and higher-risk tumors.
So a tumor could be relatively small across but deeply invasive, and it would still be considered high-risk. Conversely, a wide but shallow tumor might behave less aggressively. Both dimensions factor into treatment decisions.
Location Changes What Counts as “Large”
On certain parts of the face, the bar for concern drops well below 2 centimeters. The National Comprehensive Cancer Network uses location-specific size thresholds that are much smaller:
- Mask areas of the face (central face, ears, around the eyes, nose, temples, lips): 6 mm or larger is considered high-risk
- Forehead, scalp, cheeks, and neck: 10 mm or larger is considered high-risk
These areas have thinner skin, denser networks of nerves, and closer proximity to critical structures like the eyes, ears, and brain. A 1-centimeter SCC on your ear is treated with far more urgency than the same size tumor on your back. The ears and lips in particular are flagged as high-risk sites across virtually every set of guidelines.
How Size Affects Treatment
For most skin SCCs under 2 cm, a surgeon typically removes the tumor with a 4 mm margin of normal-looking skin around it. That’s enough to clear the cancer in the vast majority of cases. Once a tumor reaches 2 cm or has other high-risk features, the recommended margin widens to at least 6 mm. Many of these larger tumors are treated with Mohs surgery, which involves examining tissue under a microscope during the procedure to confirm all cancer cells have been removed.
Larger tumors also trigger more extensive follow-up. Imaging may be ordered to check whether the cancer has reached nearby lymph nodes. The combination of size with other risk factors, like growth into deeper tissue or nerve involvement, can push treatment toward radiation therapy after surgery or, in advanced cases, systemic treatment.
When Multiple Risk Factors Overlap
Size alone doesn’t determine prognosis. What makes the Brigham and Women’s Hospital system particularly useful is that it counts risk factors together. A tumor that’s over 2 cm, poorly differentiated, and has nerve invasion (three risk factors) lands in T2b, a category where about 24% of patients develop spread to nearby lymph nodes and 16% die from the disease. Compare that to tumors in the lowest stages (T1 or T2a), where spread to nodes occurs in less than 1% of cases and death from the cancer is under 0.5%.
Research from a large study at Brigham and Women’s Hospital found that even when nerve invasion was present, patients whose tumors lacked other risk factors like large diameter or deep invasion still had a good prognosis. It’s the accumulation of high-risk features, with size as one of the most common, that drives the worst outcomes. If your pathology report mentions any of these features alongside a large diameter, that combination carries more weight than either factor alone.